MGC Diagnostics Corp  

(Public, NASDAQ:MGCD)   Watch this stock  
Find more results for NASDAQ:ANGN
6.89
-0.11 (-1.57%)
May 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.89 - 6.89
52 week 5.01 - 7.92
Open 6.89
Vol / Avg. 327.00/6,288.00
Mkt cap 27.55M
P/E     -
Div/yield 0.45
EPS -0.28
Shares 4.00M
Beta 0.88
Inst. own 25%
May 29, 2013
Q2 2013 Angeion Corp Earnings Release Add to calendar
Mar 27, 2013
Angeion Corp Annual Shareholder Meeting
Mar 5, 2013
Q1 2013 MGC Diagnostics Corp Earnings Conference Call
Feb 27, 2013
Q1 2013 MGC Diagnostics Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '12) 2012
Net profit margin 0.06% -3.91%
Operating margin 0.09% -3.86%
EBITD margin - -1.38%
Return on average assets 0.10% -4.98%
Return on average equity 0.14% -7.31%
Employees 119 -
Carbon Disclosure Rating - -

Address

350 Oak Grove Pkwy
ST. PAUL, MN 55127-8599
United States - Map
+1-651-4844874 (Phone)
+1-651-3798227 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

MGC Diagnostics Corporation is a global medical technology company dedicated to cardiorespiratory health solutions. The Company designs, markets and sells non-invasive cardiorespiratory diagnostic products through its Medical Graphics Corporation subsidiary under the MGC Diagnostics brand and trade name. The Company�s primary products include pulmonary function (PFT) and gas exchange (GX) testing products. The Company sells its products internationally through distributors and in the United States through a direct sales force targeting specialists located in hospitals, university-based medical centers, medical clinics, physician offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). Effective August 28, 2012, the Company sold the assets of its New Leaf business to Life Time Fitness, Inc.

Officers and directors

Mark W. Sheffert Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Gregg O. Lehman Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Wesley W. Winnekins Chief Financial Officer, Executive Vice President - Finance and Corporate Development
Bio & Compensation  - Reuters
John R. Baudhuin Independent Director
Age: 50
Bio & Compensation  - Reuters
Wendy D. Lynch Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Robert E. Munzenrider Independent Director
Age: 68
Bio & Compensation  - Reuters
Hendrik Struik Independent Director
Age: 46
Bio & Compensation  - Reuters